These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26563369)

  • 21. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
    Bi YL; Min M; Shen W; Liu Y
    Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
    McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N
    Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
    De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
    Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
    Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
    Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer.
    Guan H; Dai Z; Ma Y; Wang Z; Liu X; Wang X
    Int J Mol Med; 2016 Jun; 37(6):1643-51. PubMed ID: 27082308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN; Andriu A; Smith TA
    Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
    Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
    Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
    Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
    Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
    Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1.
    Zhu HY; Bai WD; Ye XM; Yang AG; Jia LT
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1308-1313. PubMed ID: 29408336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
    Li Y; Zhang Y; Liu X; Wang M; Wang P; Yang J; Zhang S
    Int J Oncol; 2018 Jun; 52(6):2119-2129. PubMed ID: 29620169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
    Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
    Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES; Abt MA; Hill EG
    Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.